| Name | Moxetumomab |
|---|
| Description | Moxetumomab, a recombinant CD22-targeting immunotoxin, can be used for the research of hairy cell leukemia (HCL)[1][2]. |
|---|---|
| Related Catalog | |
| References |
[2]. Sohita Dhillon. Moxetumomab Pasudotox: First Global Approval. Drugs. 2018 Nov;78(16):1763-1767. |
| No Any Chemical & Physical Properties |